Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy.
The correlation between serum 50 % hemolytic complement (CH50) level and myasthenic symptom severity has not been known in patients with anti-acetylcholine receptor (anti-AChR)-positive myasthenia gravis (MG) during eculizumab treatment. A patient with anti-AChR-positive MG showed severe bulbar symptoms. Eculizumab administration decreased CH50 level and improved the symptoms. However, shortly after the second administration of eculizumab was postponed due to the development of pneumonia, his serum CH50 level returned almost to the level it was at before the initiation of eculizumab therapy and myasthenic symptoms worsened. Even after his pneumonia was completely cleared in response to an antibiotic, the severe myasthenic symptoms persisted. After eculizumab was resumed, serum CH50 level was reduced to below the limit of detection within 24 h, and the symptom steadily improved. His symptom severity was correlated temporally with serum CH50 level during eculizumab therapy. Our case suggests that serum CH50 level may be a marker of eculizumab-induced complement blockade and an indicator of a potential worsening of myasthenic symptoms during eculizumab treatment.